Pfizer has announced the FDA's approval of PENBRAYA™, an innovative pentavalent vaccine. PENBRAYA™ is the first and only vaccine designed to safeguard adolescents and young adults, aged 10 to 25, against the five most common serogroups responsible for meningococcal disease: A, B, C, W, and Y. This vaccine combines components from two existing meningococcal vaccines, Trumenba® (for group B) and Nimenrix® (for groups A, C, W-135, and Y), providing comprehensive coverage against the majority of invasive meningococcal disease cases worldwide.
Meningococcal disease, although infrequent, is a severe and potentially life-threatening illness characterized by rapid onset. Survivors may face long-term disabilities. PENBRAYA™ simplifies the vaccination process by reducing the number of doses required, enhancing convenience for adolescents and young adults. According to the CDC, consolidating vaccines into fewer shots can improve on-time vaccination rates, offering earlier protection against serious diseases.
Receiving PENBRAYA doesn't replace the need for tetanus vaccination. If you have a history of Guillain-Barré syndrome, consult your healthcare provider about potential risks and benefits. Common side effects include pain at the injection site, fatigue, headache, redness, muscle and joint pain, swelling, and
Chills. If pregnant or planning to be, discuss with your healthcare provider to determine if PENBRAYA is suitable. Your healthcare provider is the best resource for making this decision.